| Patient | Leonard Nimoy |
|---|---|
| Date of birth | 1943-03-26 |
| Identifiers | MRN HR-ML017-SYN; SSN (made up) 000-17-6604 |
| Document date | 2026-05-12 |
| Author | Carla Benedetti, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month COPD review after pulmonary rehabilitation. [S]
Mr. Nimoy returns three months after starting tiotropium-olodaterol and four days after finishing pulmonary rehabilitation. He attended all 24 sessions. He now walks about 300 meters at his own pace before stopping, uses the pursed-lip breathing he learned there, and has a home program of walking twice a day and strength exercises three times a week. He uses albuterol about twice a week, mostly before longer walks. He has taken every maintenance dose. He has had no flare-up, antibiotic or prednisone course, or emergency visit. He repeated the 6-minute walk in the pulmonary function laboratory this morning. The pneumococcal vaccine that was out of stock at the last visit is available today. [S]
| Element | Detail |
|---|---|
| Rehabilitation | Completed 24 of 24 sessions four days ago; home program in place |
| Exercise tolerance | Walks about 300 meters before stopping |
| Reliever use | Albuterol about twice a week |
| Adherence | All maintenance doses taken |
| Exacerbations | None |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Breathless after about 300 meters or a flight of stairs; no increase in cough or sputum |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Musculoskeletal | Negative | No injuries or joint pain from the exercise program |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two inhalations as needed for breathlessness (prescribed by his previous clinician; used once or twice most days before intake) | Two inhalations every 4 hours as needed, with a spacer | Respiratory tract route | 2025-09-15 | active | S |
| Tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations once daily | Two inhalations once each morning | Respiratory tract route | 2026-02-10 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-12 | Body height | 185 | cm | S |
| 2026-05-12 | Body weight | 80.8 | kg | S |
| 2026-05-12 | Body mass index (BMI) [Ratio] | 23.6 | kg/m2 | S |
| 2026-05-12 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-05-12 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-05-12 | Heart rate | 78 | /min | S |
| 2026-05-12 | Respiratory rate | 18 | /min | S |
| 2026-05-12 | Body temperature | 36.7 | Cel | S |
| 2026-05-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 94 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-12 | Six minute walk test | 330 | m | Predicted about 480 m for his age, sex, height, and weight; lower limit about 380 m | Low | S |
Vital signs recorded on 2026-05-12; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Comfortable at rest; speaks in full sentences |
| Lungs | Reduced breath sounds with prolonged expiration; no wheeze or crackles |
| Cardiovascular | Regular rhythm at 78 per minute; no edema |
| Inhaler technique | Correct with his soft mist inhaler |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic obstructive pulmonary disease, GOLD 3 (severe airflow limitation), group B, confirmed on spirometry; synthetic modern classification linked to his publicly disclosed COPD | active | confirmed | J44.9 | S — Synthetic modern spirometric classification; the COPD diagnosis itself is D from his own public disclosure. |
| Former smoker, quit about 30 years ago through a cessation program | active | confirmed | Z87.891 | S — Synthetic modern entry linked to his public account of quitting smoking. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | COPD Assessment Test (CAT) | Every visit | Completed today | 15, down from 19 at four weeks and 22 at intake |
| Survey | mMRC dyspnea grade | Every visit | Completed today | Grade 2, down from 3 |
| Survey | Exacerbation history and GOLD group | Every visit | Completed today | None; group B |
| Examination | Pulse oximetry | Every visit | Completed today | 94 percent at rest on room air |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Former smoker; no tobacco |
| Examination | BMI and nutritional status | Every visit | Completed today | BMI 23.6; weight up 0.6 kg with exercise |
| Examination | Inhaler technique and adherence | Every visit | Completed today | Correct; full adherence |
| Examination | 6-minute walk test | At pulmonary rehabilitation entry and exit, and for oxygen assessment | Completed today | 330 m at rehabilitation exit, up 60 m; lowest saturation 90 percent |
| Examination | Long-term oxygen assessment | As indicated: resting saturation 88 percent or less, confirmed twice at least three weeks apart | Not indicated | Resting saturation 94 percent; no oxygen criterion met |
| Referral | Pulmonary rehabilitation | Stable mMRC 2 or more or CAT 10 or more; within three weeks of any hospital stay for an exacerbation | Completed today | Program completed four days ago, 24 of 24 sessions; home program and maintenance class offered |
| Examination | Spirometry | At diagnosis, then at least yearly and with significant clinical change | Up to date | Next in nine months, at the yearly review |
| Laboratory | Blood eosinophil count | At baseline and when an inhaled corticosteroid is considered | Not indicated | No change in inhaled corticosteroid being considered |
| Medication safety | Vaccination status | Reviewed yearly | Completed today | PCV20 given today, nine weeks later than planned. Deviation: the dose planned at the four-week visit was missed because the vaccine was out of stock. No harm resulted: he had no respiratory infection in the interval. Corrective action: vaccine stock is checked before a planned dose is booked, and missed doses are added to the next visit's orders |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]
Guideline basis: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020); Adult Immunization Schedule by Age (2026)
Follow-up: COPD review in three months, or the same day for any flare-up. Next scheduled visit 2026-08-11: six-month COPD review. [S]